Pre-symptomatic Infants Retain Swallowing Ability in Evrysdi Trial

Pre-symptomatic Infants Retain Swallowing Ability in Evrysdi Trial

307330

Pre-symptomatic Infants Retain Swallowing Ability in Evrysdi Trial

After being treated with Evrysdi (risdiplam) for at least a year, pre-symptomatic infants with spinal muscular atrophy (SMA) have retained the ability to swallow, and most have been able to stand and walk within developmentally normal windows. That’s according to new data from the RAINBOWFISH clinical trial presented at the World Muscle Society Virtual Congress by scientists at Roche, which markets Evrysdi in collaboration with PTC Therapeutics. “These new data for Evrysdi may help extend…

You must be logged in to read/download the full post.